mardi 14 mars 2017

Onco Actu du 14 mars 2017


1. Biologie

Pancreatic cancer, diabetes link explored by Stanford researchers [Stanford Medicine]

Using Darwin’s notebook to outsmart resistance [Cancer World]

1.1 Biologie - Gènes

More breast cancer patients than previously thought could benefit from existing targeted treatment [Cancer Research UK]

Genetic similarities open up treatment options for non-BRCA breast tumours [ecancer News]

3.1 Tabac

Can we trust Big Tobacco to promote public health? [The Conversation]

3.8 Prévention - Alimentation

Why you should beware of those aiming to “separate fact from fiction” in nutrition research [HealthNewsReview]

4. Dépistage, diagnostic et pronostic

Combining MRI scans could help spot where tumours are short of oxygen, helping to personalise treatment [Cancer Research UK]

4.9 Dép., diag. & prono. - Sein

Myriad Genetics Launches the EndoPredict® Test in the United States for Patients with Breast Cancer [Myriad]

5. Traitements

Richard Lehman’s journal review—13 March 2017 [BMJ]

Old-Style Chemo Is Still A Mainstay In The Age Of Targeted Cancer Therapy [NPR]

5.12 Immunothérapies

Checkpoint Inhibition Success Depends on CD28/B7 Costimulation [GEN]

Immunotherapy: The three major treatments that are changing cancer prognoses [Pharmafile]

5.12.2 Immunothérapies - CAR-T

Possible Cures. Mystery Deaths. Daunting Costs. Can CAR-T Be Tamed? [Xconomy]

5.12.3 Immunothérapies-combinaisons

Combination immunotherapy shows promise in castration-resistant prostate cancer [Pharmafile]

5.2 Pharma

After an AML flop, Karyopharm hit with hold for selinexor tests [FierceBiotech]

5.2.1 Pharma - Partenariats

Celgene embraces MTAP cancer deal with fast-moving collaborator Agios [EndPoints]

5.2.3 Pharma - économie

Roche and Mylan settle a scrap over Herceptin, clearing path to a global launch of a knockoff drug [EndPoints]

Mylan deal clears path for biosimilar copy of Roche's Herceptin [Reuters]

5.3 Traitements - FDA, EMA, NICE...

Biopharma execs give Scott Gottlieb’s nomination for FDA commish (almost) a standing O in Endpoints poll [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA)

Novartis rolls out flex pricing scheme for newly approved Ibrance rival Kisqali [FiercePharma]

Ipsen announces MHRA approval of new indication for Decapeptyl® for the treatment of pre-menopausal women with early stage breast cancer [Ipsen]

Watch out Pfizer, Novartis’ LEE011 bags quick OK for frontline use against breast cancer [EndPoints]

Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor [Novartis]

FDA approves Novartis drug as first-line treatment for breast cancer [Reuters]

6.10 Politiques

Brexit and the treatment of children with cancer | Letters [The Guardian]

6.6 Publications

Collision Course — Why Are Funders Straying from Their Lane? [The Scholarly Kitchen]